APDN Stock Overview
Applied DNA Sciences, Inc., a biotechnology company, develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) in the Americas, Europe, Asia, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Applied DNA Sciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.36 |
| 52 Week High | US$1.86 |
| 52 Week Low | US$0.36 |
| Beta | 0.094 |
| 1 Month Change | -2.12% |
| 3 Month Change | -40.08% |
| 1 Year Change | -65.03% |
| 3 Year Change | -93.92% |
| 5 Year Change | -98.50% |
| Change since IPO | -99.99% |
Recent News & Updates
Recent updates
The Market Doesn't Like What It Sees From Applied DNA Sciences, Inc.'s (NASDAQ:APDN) Revenues Yet As Shares Tumble 26%
Dec 20
Is Applied DNA Sciences (NASDAQ:APDN) In A Good Position To Invest In Growth?
Jan 01Applied DNA climbs 51% after winning large purchase order
Oct 10Applied DNA stock rises 12% on launching monkeypox testing service in New York
Sep 06Applied DNA adds 17% as company seeks approval for monkeypox test in New York
Aug 19Upgrade: Analysts Just Made A Notable Increase To Their Applied DNA Sciences, Inc. (NASDAQ:APDN) Forecasts
Aug 17Applied DNA Sciences gains as it secures ~$3.6M proceeds from warrant exercise
Aug 09Applied DNA stock soars 73% on starting validation of PCR-based monkeypox test
Aug 02Applied DNA announces positive data from veterinary vaccine trial to treat COVID-19
Jul 25News Flash: Analysts Just Made A Notable Upgrade To Their Applied DNA Sciences, Inc. (NASDAQ:APDN) Forecasts
May 18Is Applied DNA Sciences (NASDAQ:APDN) In A Good Position To Deliver On Growth Plans?
Sep 17Applied DNA's LinearDNA COVID-19 vaccine booster yields 5-fold increase in neutralizing antibody in felines
May 06Shareholder Returns
| APDN | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | -9.2% | -3.7% | -3.1% |
| 1Y | -65.0% | -5.7% | 20.9% |
Return vs Industry: APDN underperformed the US Life Sciences industry which returned -4.1% over the past year.
Return vs Market: APDN underperformed the US Market which returned 22.4% over the past year.
Price Volatility
| APDN volatility | |
|---|---|
| APDN Average Weekly Movement | 11.9% |
| Life Sciences Industry Average Movement | 7.0% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: APDN's share price has been volatile over the past 3 months.
Volatility Over Time: APDN's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1983 | 54 | James Hayward | www.adnas.com |
Applied DNA Sciences, Inc., a biotechnology company, develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) in the Americas, Europe, Asia, and internationally. It operates through three segments: Therapeutic DNA Production Services; MDx Testing Services; and DNA Tagging and Security Products and Services. The Therapeutic DNA Production Services segment develops and commercializes the LinearDNA platform, which enables a cell-free manufacture of high-fidelity synthetic DNA sequences for use in nucleic acid-based therapeutics.
Applied DNA Sciences, Inc. Fundamentals Summary
| APDN fundamental statistics | |
|---|---|
| Market cap | US$6.43m |
| Earnings (TTM) | -US$7.29m |
| Revenue (TTM) | US$9.00m |
0.7x
P/S Ratio-0.8x
P/E RatioIs APDN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| APDN income statement (TTM) | |
|---|---|
| Revenue | US$9.00m |
| Cost of Revenue | US$5.61m |
| Gross Profit | US$3.39m |
| Other Expenses | US$10.67m |
| Earnings | -US$7.29m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.43 |
| Gross Margin | 37.65% |
| Net Profit Margin | -81.00% |
| Debt/Equity Ratio | 0% |
How did APDN perform over the long term?
See historical performance and comparison